Pulmonary Vascular Disease |

Statins Therapy and the Severity of Pulmonary Embolism FREE TO VIEW

Prangthip Charoenpong, MD; Rongras Damrongwatanasuk, MD; Nongnooch Poowanawittayakom, MD; Clifton Clarke, MD
Author and Funding Information

Advocate Illinois Masonic Medical Center, Chicago, IL

Chest. 2013;144(4_MeetingAbstracts):847A. doi:10.1378/chest.1702880
Text Size: A A A
Published online


SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: The preventive effect of statins on pulmonary embolism is controversial. Recent studies revealed statins decreases incidence of pulmonary embolism (PE) but no one has reported the effect of statins on the severity of PE. The aim of this study is to determine the association between statins and the severity of PE.

METHODS: Retrospective medical records review of 156 patients diagnosed with PE determined the severity by simplified pulmonary embolism severity index (SPESI). The high SPESI risk factors include age > 80 years old, history of cancer, history of chronic cardiopulmonary disease, heart rate > 110, systolic blood pressure < 100 mmHg and oxygen saturation < 90%. The length of hospital stay and all-cause mortality were also compared between statins and non-statins use. The demographics, clinical manifestation, laboratory findings, and treatment were also collected.

RESULTS: From 156 patients (mean 59.6±19 years old, 42.9% male), 35 patients were on statins therapy (statins group). There is no statistical significant in high SPESI risk between statins and non-statins users (65.7% vs 53.8%, p = 0.21). The average length of hospital stay are 7.9 days and 7.2 days (p = 0.69) in statins and non-statins groups respectively. All-cause mortality rate is also comparable among 2 groups (14.3% vs 13.4%, p = 0.9). No difference between age, gender and ethnicity in statins compared to non-statins group.

CONCLUSIONS: Even though there is supportive evidence of statins in the prevention of PE by the proposed mechanism of reduction of inflammatory and platelet aggregation. No association of statins and the severity of PE, the length of hospital stay and all-cause mortality was shown in this analysis. Further study is needed to explore the effect of type, dosage and duration of statins therapy on the severity of PE.

CLINICAL IMPLICATIONS: Statins was not proven to have an effect on the severity of PE. Whether statins should be used to prevent or decrease the severity of PE remains controversial.

DISCLOSURE: The following authors have nothing to disclose: Prangthip Charoenpong, Rongras Damrongwatanasuk, Nongnooch Poowanawittayakom, Clifton Clarke

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543